Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback